GlassScriptPhysician profile
Jeffrey A Wacks
NPI 1568708311
$1,491.29
in general payments reported to CMS, 2019-2025
14 companies · $300 in 2025
The $300 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $32.39 · 2020: $43.42 · 2021: $241 · 2022: $190 · 2023: $398 · 2024: $286 · 2025: $300.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $985.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $984.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $541.41 | 2019-2025 | Xifaxan |
| Novo Nordisk INC | $346.68 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $181.11 | 2020-2025 | Zepbound, Mounjaro, Jardiance |
| Antares Pharma, INC. | $89.19 | 2021-2025 | Xyosted |
| Pfizer INC. | $63.92 | 2023-2025 | |
| Exact Sciences Corporation | $39.13 | 2025 | The Cologuard Plus Collection Kit |
| Hologic Sales and Service, LLC | $37.92 | 2019-2025 | Aptima, Thinprep 2000 Processor |
| Heartflow, INC. | $36.22 | 2024 | |
| Inspire Medical Systems, INC. | $35.04 | 2025 | Inspire |
| Acella Pharmaceuticals, LLC | $34.49 | 2023-2025 | NP Thyroid 60 |
| Astellas Pharma US INC | $26.67 | 2025 | Veozah |
| Halozyme INC | $24.91 | 2023 | |
| Clarus Therapeutics INC. | $18.33 | 2021 | |
| Redhill Biopharma INC. | $16.27 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Wacks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.